nybanner

        Products

        API-Drug Peptide Linaclotide: A pill for bowel relief and comfort

        Short Description:

        Linaclotide is a breakthrough medication that can help you manage your chronic constipation and irritable bowel syndrome with constipation. It is made by Ironwood Pharmaceuticals, and has been approved by the FDA and other health authorities to be sold under the brand name Linzess in the US and Mexico, and as Constella in other countries. Linaclotide is a once-daily pill that you can take with or without food, and can help you have more frequent and complete bowel movements, and reduce the pain and discomfort caused by your condition.


        Product Detail

        Product Tags

        About This Item

        Linaclotide is a cyclic peptide that consists of 14 amino acids, three of which are cysteines that form disulfide bonds. Linaclotide is structurally related to the endogenous peptides guanylin and uroguanylin, which are natural ligands of the guanylate cyclase C (GC-C) receptor. The GC-C receptor is expressed on the luminal surface of the intestinal epithelial cells, where it regulates fluid secretion and intestinal motility. Linaclotide binds to the GC-C receptor with high affinity and specificity, and activates it by increasing the intracellular levels of cyclic guanosine monophosphate (cGMP). cGMP is a second messenger that mediates various cellular responses, such as chloride and bicarbonate secretion, smooth muscle relaxation, and pain modulation. Linaclotide acts locally in the gastrointestinal tract, and does not penetrate the blood-brain barrier or affect the central nervous system. Linaclotide also produces an active metabolite, MM-419447, which has similar pharmacological properties to linaclotide. Both linaclotide and its metabolite are resistant to proteolytic degradation by intestinal enzymes, and are mainly eliminated unchanged in the feces (MacDonald et al., Drugs, 2017).

        By activating the GC-C receptor, linaclotide increases the secretion of fluid into the intestinal lumen, which softens the stool and facilitates bowel movements. Linaclotide also reduces the visceral hypersensitivity and inflammation that are associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders. Linaclotide modulates the activity of the enteric nervous system and the colonic nociceptors, which are sensory neurons that transmit pain signals from the gut to the brain. Linaclotide decreases the expression of pain-related genes, such as substance P and calcitonin gene-related peptide (CGRP), and increases the expression of opioid receptors, which mediate analgesia. Linaclotide also reduces the release of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), and increases the release of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor beta (TGF-β). These effects of linaclotide improve the symptoms of constipation and abdominal pain in patients with IBS or chronic constipation (Lembo et al., The American Journal of Gastroenterology, 2018).

        Linaclotide has been shown to be effective and well-tolerated in several clinical trials involving patients with CC or IBS-C. In these trials, linaclotide improved bowel habits, such as stool frequency, consistency, and completeness; reduced abdominal pain and discomfort; and enhanced quality of life and patient satisfaction. Linaclotide also demonstrated a favorable safety profile, with diarrhea being the most common adverse event. The incidence of diarrhea was dose-dependent and usually mild to moderate in severity. Other adverse events were generally similar to placebo or low in frequency. No serious adverse events or deaths were attributed to linaclotide treatment (Rao et al., Clinical Gastroenterology and Hepatology, 2015).

        Product Dispaly

        shows (2)
        shows (3)
        shows (1)

        Why Choose Us

        Linaclotide is a novel and effective medication for patients with CC and IBS-C who have not responded well to conventional therapies. It works by mimicking the action of endogenous peptides that regulate intestinal function and sensation. Linaclotide can improve bowel habits, reduce abdominal pain, and enhance quality of life for these patients.

        productss

        Figure 1. Abdominal pain/abdominal discomfort and IBS degree of relief weekly responders over the 12-week. ?, placebo;?, linaclotide 290?μg.?
        (Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., and Lim, S. (2018) Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. Journal of Gastroenterology and Hepatology, 33: 980–989. doi: 10.1111/jgh.14086.)
        We are a polypeptide manufacturer in China, with several years of mature experience in polypeptide production. Hangzhou Taijia Biotech Co., Ltd. is a professional polypeptide raw material manufacturer, which can provide tens of thousands of polypeptide raw materials and can also be customized according to needs. The quality of polypeptide products is excellent, and the purity can reach 98%, which has been recognized by users all over the world.Welcome to consult us.


      1. Previous:
      2. Next:

      3. 主站蜘蛛池模板: 做暧暧小视频全集免费| 国产激情一区二区三区成人91| 久久伊人免费视频| 永久免费看bbb| 噼里啪啦动漫在线观看免费| 日本亚洲黄色片| 天天做天天爱天天综合网| 久久av无码专区亚洲av桃花岛| 欧美另类xxxx图片| 免费A级毛片无码无遮挡| 色综合a怡红院怡红院首页| 国产精品久线在线观看| caoporm碰最新免费公开视频| 无码日韩精品一区二区免费| 亚洲国产成人va在线观看| 男人把女人桶爽30分钟一| 国产一级小视频| 天天视频天天爽| 国精品无码一区二区三区在线| 三级免费黄色片| 日本精品啪啪一区二区三区| 亚洲国产精品成人综合色在线婷婷| 积积对积积的桶120分钟| 国产一级做a爰片久久毛片| 欧美色图在线观看| 国内一级特黄女人精品片| 一级毛片a女人刺激视频免费| 日韩AV无码精品一二三区| 亚洲午夜电影网| 波多野结衣中出在线| 免费观看我爱你电影| 色多多视频在线观看| 国产成人va亚洲电影| 香蕉视频污在线观看| 国色天香论坛社区在线视频| 一本色道久久综合亚洲精品| 日本三级在线视频| 久久综合香蕉国产蜜臀av| 欧美人与动人物乱大交| 亚洲电影在线免费观看| 男人的天堂免费a级毛片无码|